Channing J. Paller - Concepedia

Author

Channing J. Paller

Also Known As

C J Paller, C. J. Paller, C. Paller, C.J. Paller, Channing J Paller, Channing J. Paller, Channing Judith Paller, Channing Paller, Lynda G. Balneaves

505

Publications

10.1K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine University of Minnesota Medical Center Rutgers, The State University of New Jersey

About

Channing J. Paller is an author at Johns Hopkins University specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	29	1.6K
2	Health Sciences	8	8	338
3	Public Health	3	3	116
4	Engineering	1	1	183
5	Biostatistics	1	1	18

Channing J. Paller

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer Emmanuel S. Antonarakis, Changxue Lu, Hao Wang, New England Journal of Medicine	2014	2.6K
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer Ryan Phillips, William Y. Shi, Matthew P. Deek, JAMA Oncology	2020	1.1K
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, JAMA Oncology	2015	611
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, Journal of Clinical Oncology	2017	468
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials Matthew P. Deek, Kim Van der Eecken, Philip Sutera, Journal of Clinical Oncology	2022	222
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study Benjamin A. Teply, Hao Wang, Brandon Luber, The Lancet Oncology Bipolar Androgen TherapyUrologyOncologyMulticohort StudyMedicine	2017	192
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer Mari Nakazawa, Changxue Lu, Y. Chen, Annals of Oncology Prognostic BiomarkersUrologyOncologyEngineeringGenitourinary Cancer	2015	183
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Channing J. Paller, Emmanuel S. Antonarakis PubMed UrologySurgical OncologyLocal TherapyBiochemical RecurrenceGenitourinary Cancer	2013	183
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer Channing J. Paller, Xiquan Ye, Paulina Woźniak, Prostate Cancer and Prostatic Diseases UrologyMedicineLocalized Prostate CancerPharmacologyBenign Prostatic Hyperplasia	2012	182
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer Samuel R. Denmeade, Hao Wang, Neeraj Agarwal, Journal of Clinical Oncology	2021	133

Page 1